Clinical Trials | May 26, 2026
Lilly posts strong early clinical results for one-shot gene-editing cholesterol therapy
A one-shot gene-editing cholesterol therapy could soon be a reality
A one-shot gene-editing cholesterol therapy could soon be a reality
Fresh data from the State of the World’s Nursing 2025 report shows the global nursing workforce has expanded from 27.9 million in 2018 to 29.8 million in 2023
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Clears major obesity endpoints at 80 weeks
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
